Pfizer (PFE) Total Non-Current Liabilities (2009 - 2026)
Pfizer (PFE) posted quarterly Total Non-Current Liabilities of $103.0 billion for Q1 2026, down 1.04% year-over-year from $104.1 billion in Q1 2025, and up 1696.23% quarter-over-quarter from $5.7 billion in Q4 2025.
Pfizer (PFE) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Total Non-Current Liabilities for 18 consecutive years, with $103.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 1.04% year-over-year to $103.0 billion; the TTM figure through Mar 2026 stood at $103.0 billion (down 1.04% YoY), while the FY2025 annual figure was $5.7 billion, down 7.57% from the prior year.
- Total Non-Current Liabilities climbed to $103.0 billion in Q1 2026 per PFE's latest filing, from $5.7 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $113.4 billion in Q1 2024 and bottomed at $5.7 billion in Q4 2025.
- Historically, Total Non-Current Liabilities has averaged $69.8 billion across 5 years, with a median of $96.8 billion in 2022.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities dropped 9.16% — and 2024, when it jumped 607.25%.
- Pfizer's Total Non-Current Liabilities stood at $6.0 billion in 2022, then grew by 0.03% to $6.0 billion in 2023, then grew by 3.45% to $6.2 billion in 2024, then declined by 7.57% to $5.7 billion in 2025, then surged by 1696.23% to $103.0 billion in 2026.
- Business Quant data shows PFE's Total Non-Current Liabilities at $103.0 billion in Q1 2026, $5.7 billion in Q4 2025, and $102.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.15 Bn | 634.39 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 469.47 Bn | 462.91 Bn | 12.70 Bn | 100.51 Bn |
| 3 | Merck | 380.63 Bn | 373.49 Bn | 12.21 Bn | 122.23 Bn |
| 4 | Novartis Ag | 302.58 Bn | 294.89 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Astrazeneca | 257.84 Bn | 252.94 Bn | 12.86 Bn | 33.91 Bn |
| 6 | Amgen | 236.70 Bn | 222.71 Bn | 7.24 Bn | 92.80 Bn |
| 7 | Gilead Sciences | 182.92 Bn | 179.74 Bn | 6.22 Bn | 47.87 Bn |
| 8 | Pfizer | 161.16 Bn | 149.47 Bn | 10.94 Bn | 100.86 Bn |
| 9 | Gsk | 105.59 Bn | 101.42 Bn | 8.24 Bn | -30.89 Bn |
| 10 | Sanofi | 54.99 Bn | 47.61 Bn | 10.79 Bn | 32.04 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 100.86 Bn |
| Mar 29, 2026 | 103.01 Bn |
| Dec 31, 2025 | 5.74 Bn |
| Sep 28, 2025 | 102.03 Bn |
| Jun 29, 2025 | 103.15 Bn |
| Mar 30, 2025 | 104.09 Bn |
| Dec 31, 2024 | 6.21 Bn |
| Sep 29, 2024 | 111.35 Bn |
| Jun 30, 2024 | 112.12 Bn |
| Mar 31, 2024 | 113.42 Bn |
| Dec 31, 2023 | 6.00 Bn |
| Sep 30, 2023 | 15.74 Bn |
| Jul 2, 2023 | 112.82 Bn |
| Apr 2, 2023 | 81.37 Bn |
| Dec 31, 2022 | 6.00 Bn |
| Sep 30, 2022 | 17.22 Bn |
| Jul 3, 2022 | 96.83 Bn |
| Apr 3, 2022 | 89.58 Bn |
| Dec 31, 2021 | 6.54 Bn |
| Oct 3, 2021 | 5.22 Bn |